アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Rhino-Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Rhino-Conjunctivitis – Overview 9
Pipeline Products for Allergic Rhino-Conjunctivitis – Comparative Analysis 10
Allergic Rhino-Conjunctivitis – Therapeutics under Development by Companies 11
Allergic Rhino-Conjunctivitis – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Allergic Rhino-Conjunctivitis – Products under Development by Companies 15
Allergic Rhino-Conjunctivitis – Companies Involved in Therapeutics Development 17
ALK-Abello A/S 17
Allergopharma Joachim Ganzer KG 18
Allergy Therapeutics plc 19
Anergis SA 20
Bial – Portela & Ca, S.A. 21
BioTech Tools s.a. 22
Circassia Pharmaceuticals plc 23
Greer Laboratories, Inc. 24
HAL Allergy BV 25
Immunomic Therapeutics, Inc. 26
Laboratorios LETI S.L. 27
Stallergenes S.A. 28
Allergic Rhino-Conjunctivitis – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Acaroid – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AL-0704rP – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ALK Birch Pollen Vaccine – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Allergovac – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AllerT – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Avanz Phleum Pratense – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Depigoid Birch – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dermatophagoides Pteronyssinus Allergen Extract – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
gpASIT + TM – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Grass Pollen Allergoid – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Grass-SPIRE – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
House Dust Mite-SPIRE – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
JRC2-LAMP-vax – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MK-8237 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Olea Europaea Pollen Extract – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Pollinex Quattro Grass – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Ragweed Pollen Extract – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rBet v1 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
rBet v1-FV – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rPhleum – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Allergic Rhino-Conjunctivitis – Recent Pipeline Updates 68
Allergic Rhino-Conjunctivitis – Dormant Projects 76
Allergic Rhino-Conjunctivitis – Discontinued Products 77
Allergic Rhino-Conjunctivitis – Product Development Milestones 78
Featured News & Press Releases 78
Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 78
May 18, 2014: BioTech Tools will be present at the EAACI congress 79
Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 80
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 81
Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 82
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85